Table 3

Comparison of pooled PCR-uncorrected proportions of adequate clinical and parasitological response between AQ-SP and ACT.

ACT

Odds-ratio (95% CI), as compared to AQ-SP

day 2

day 3

day 14

day 28

AM-LM

25.6

(8.21-79.5)*

ND

2.81

(0.28-27.7)

6.32

(1.35-29.6)*

AS-AQ

26.4

(12.4-56.4)*

16.0

(3.35-76.1)*

0.72

(0.20-2.62)

0.80

(0.40-1.61)

AS-CD

34.7

(11.2-107)*

ND

0.26

(0.07-0.96)*

0.35

(0.16-0.75)*

AS-MQ

11.4

(4.76-27.1)*

3.26

(0.84-12.7)

0.36

(0.10-1.41)

1.45

(0.57-3.71)

AS-SP

18.9

(8.64-41.2)*

5.30

(1.57-17.9)*

0.91

(0.22-3.64)

1.34

(0.60-2.93)

DH-PP

37.4

(12.2-115)*

ND

0.80

(0.18-3.50)

9.16

(2.0-42.5)*

Patients who were excluded or lost-to-follow-up were not included in the analysis. Data from a total of 709 patients were analysed, with treatment as a single covariate. Asterisks denote P < 0.05. ND (not done) denotes infinite OR due to 100% ACPR. On day 7, 100% ACPR was observed with all bitherapies. ACT, artemisinin-based combination therapies; AS-AQ, artesunate-amodiaquine; AS-MQ, artesunate-mefloquine; AS-SP, artesunate-sulphadoxine-pyrimethamine; AM-LM, artemether-lumefantrine; AS-CD, artesunate-chlorproguanil-dapsone; DH-PP, dihydroartemisinin-piperaquine; AQ-SP, amodiaquine-sulphadoxine-pyrimethamine.

Whegang et al. Malaria Journal 2010 9:56   doi:10.1186/1475-2875-9-56